Ally Financial (ALLY), a leading global auto finance company and former unit of GM (GMAC), plans to raise $2.5 billion by offering 95.0 million shares at a price range of $25.00 to $28.00. At the midpoint of the proposed range, Ally Financial has a market value of $12.8 billion. Ally Financial was founded in 1919. The Detroit, MI-based company plans to list on the NYSE under the symbol ALLY. Citi, Goldman Sachs, Morgan Stanley, Barclays, BofA Merrill Lynch, Deutsche Bank and J.P. Morgan are the joint bookrunners on the deal.
Aldeyra Therapeutics (ALDX), a clinical-stage biotech developing treatments for rare skin and eye diseases, plans to raise $25 million by offering 2.3 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Aldeyra Therapeutics would command a market value of $75 million. Aldeyra Therapeutics was founded in 2004. The Burlington, MA-based company plans to list on the NASDAQ under the symbol ALDX. Aegis Capital is the lead bookrunner on the deal.
Enable Midstream Partners LP (ENBL), which owns, operates and develops natural gas and crude oil infrastructure assets, plans to raise $500 million by offering 25.0 million shares at a price range of $19.00 to $21.00. At the midpoint of the proposed range, Enable Midstream Partners LP would command a market value of $8.3 billion. Enable Midstream Partners LP was founded in 2013. The Oklahoma City, OK-based company plans to list on the NYSE under the symbol ENBL. Morgan Stanley, Barclays, Goldman Sachs, Citi, Deustche Bank, J.P. Morgan, UBS and Wells Fargo are the joint bookrunners on the deal.
Farmland Partners (FPI), an internally managed REIT that owns farmland properties in North America, plans to raise $70 million by offering 4.7 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Farmland Partners would command a market value of $102 million. Farmland Partners was founded in 2013. The Westminster, CO-based company plans to list on the NYSE under the symbol FPI. Baird, BMO Capital Markets and Janney Montgomery Scott are the joint bookrunners on the deal.
iKang Healthcare Group (KANG), China’s largest private operator of medical exam and disease screening centers, plans to raise $142 million by offering 10.9 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, iKang Healthcare Group would command a market value of $880 million. iKang Healthcare Group was founded in 2004. The Beijing, China-based company plans to list on the NASDAQ under the symbol KANG. BofA Merrill Lynch and UBS Investment Bank are the joint bookrunners on the deal.
Lombard Medical (EVAR), which develops stent-grafts for endovascular aorta repair, plans to raise $60 million by offering 3.6 million shares at a price range of $15.00 to $18.00. At the midpoint of the proposed range, Lombard Medical would command a market value of $252 million. Lombard Medical was founded in 2003. The Oxfordshire, United Kingdom-based company plans to list on the NASDAQ under the symbol EVAR. Jefferies & Co. and Barclays are the joint bookrunners on the deal.
Paycom Software (PAYC), which provides on-demand payroll and human capital management software, plans to raise $126 million by offering 6.6 million shares at a price range of $18.00 to $20.00. At the midpoint of the proposed range, Paycom Software would command a market value of $1.1 billion. Paycom Software was founded in 1998. The Oklahoma City, OK-based company plans to list on the NYSE under the symbol PAYC. Barclays and J.P. Morgan are the joint bookrunners on the deal.
Phibro Animal Health (PAHC), a leading manufacturer of pharmaceutical and nutrition products for livestock, plans to raise $200 million by offering 11.8 million shares at a price range of $16.00 to $18.00. At the midpoint of the proposed range, Phibro Animal Health would command a market value of $653 million. Phibro Animal Health was founded in 1946. The Teaneck, NJ-based company plans to list on the NASDAQ under the symbol PAHC. BofA Merrill Lynch, Morgan Stanley and Barclays are the joint bookrunners on the deal.
SCYNEXIS (SCYX), a biotech developing treatments for life-threatening fungal infections, plans to raise $55 million by offering 7.3 million shares at a price range of $7.00 to $8.00. At the midpoint of the proposed range, SCYNEXIS would command a market value of $143 million. SCYNEXIS was founded in 1999. The Durham, NC-based company plans to list on the NASDAQ under the symbol SCYX. RBC Capital Markets and Canaccord Genuity are the joint bookrunners on the deal. (Revised terms on 4/2/14. Previously planned to offer 4.2mm shares at $12-$14.)
Zoe’s Kitchen (ZOES), which operates 113 fast-casual restaurants serving Mediterranean-inspired comfort food, plans to raise $70 million by offering 5.8 million shares at a price range of $11.00 to $13.00. At the midpoint of the proposed range, Zoe’s Kitchen would command a market value of $221 million. Zoe’s Kitchen was founded in 1995. The Birmingham, AL-based company plans to list on the NYSE under the symbol ZOES. Jefferies & Co., Piper Jaffray and Baird are the joint bookrunners on the deal.
